Financial Performance - Operating revenue decreased by 21.23% to CNY 466,824,063.25 compared to the same period last year[9] - Net profit attributable to shareholders increased by 9.7% to CNY 27,663,375.99 compared to the same period last year[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 12.33% to CNY 24,029,311.84 compared to the same period last year[9] - Basic earnings per share increased by 12.5% to CNY 0.18 compared to CNY 0.16 in the same period last year[9] - Total operating revenue for the current period is 466,824,063.25, a decrease from 592,658,534.08 in the previous period, representing a decline of approximately 21.2%[25] - Total operating costs decreased to 444,882,579.69 from 566,281,845.10, reflecting a reduction of about 21.4%[25] - Net profit for the current period is 28,665,668.68, compared to 25,745,020.62 in the previous period, indicating an increase of approximately 11.8%[26] - Operating profit for the current period is 30,899,757.35, up from 29,062,040.97, reflecting an increase of about 6.3%[25] - Total profit for the current period is 30,896,636.91, compared to 29,214,024.19 in the previous period, indicating an increase of approximately 5.8%[25] Cash Flow - Cash flow from operating activities was CNY 31,552,918.27, a significant improvement from a negative cash flow of CNY -11,772,620.18 in the same period last year[9] - Cash flow from operating activities increased to 442,290,810.41 from 371,609,561.43, showing an increase of about 18.9%[29] - Cash flow from investing activities generated a net inflow of 65,374,862.02, compared to a net outflow of -26,556,784.85 in the previous period[31] - Net cash flow from operating activities reached $33.75 million, up from $11.91 million, representing an increase of 183.4%[33] - Net cash flow from investment activities was $67.11 million, a turnaround from a negative $41.83 million in the prior period[34] - Cash inflow from operating activities totaled $145.58 million, an increase from $111.25 million, which is a growth of 30.8%[33] - The net increase in cash and cash equivalents for the period was $100.85 million, compared to a decrease of $29.92 million in the previous period[35] Assets and Liabilities - Total assets increased by 3.21% to CNY 1,491,799,980.63 compared to the end of the previous year[9] - Total current assets increased to CNY 1,153,758,911.73 from CNY 1,046,420,325.17, representing a growth of approximately 10.4%[17] - Cash and cash equivalents rose significantly to CNY 211,446,133.53 from CNY 114,518,353.24, an increase of about 84.7%[17] - Accounts receivable increased to CNY 345,844,518.12 from CNY 283,655,328.77, reflecting a growth of approximately 22%[17] - Inventory decreased to CNY 115,358,903.01 from CNY 138,217,982.64, a decline of about 16.5%[17] - Total liabilities rose to CNY 522,671,994.08 from CNY 504,921,103.38, an increase of approximately 3.7%[19] - Total equity increased to CNY 969,127,986.55 from CNY 940,462,317.87, reflecting a growth of about 3.1%[19] - Non-current assets decreased to CNY 338,041,068.90 from CNY 398,963,096.08, a decline of approximately 15.2%[18] Shareholder Information - The total number of shareholders was 11,622 as of the report date[10] - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., holds 22.07% of the shares, totaling 33,852,409 shares[11] Investment Activities - The company reported a significant increase in long-term equity investments to CNY 77,876,777.67 from CNY 72,438,975.13, an increase of about 7.5%[17] - The company has ongoing development expenditures amounting to CNY 1,845,000.00, up from CNY 1,500,000.00, indicating a focus on new product development[18] - Investment income increased significantly to 8,958,273.79 from 2,685,351.99, marking a growth of approximately 233.5%[25] - The company received $539.66 million in cash related to investment activities, up from $128.61 million, indicating a substantial increase of 319.5%[34] - Cash outflow for investment activities was $536.08 million, compared to $170.45 million, reflecting a rise of 213.5%[34]
健民集团(600976) - 2014 Q1 - 季度财报